# 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

> **NCT02000596** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab plus Pertuzumab
- **DRUG:** Hormonal Therapy with Anastrozole and Fulvestrant
- **DRUG:** Chemotherapy with Eribulin

## Key facts

- **NCT ID:** NCT02000596
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2015-11
- **Final completion:** 2016-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** funding withdrawn by sponsor
- **Last updated:** 2022-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000596, "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02000596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*